Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Neonc Technologies Holdings, Inc.

NASDAQ: NTHI · Life Sciences · 17 alerts · CIK 1979414

Share price
$4.54Close, Nov 16
Market cap
$131M
Shares outstanding
28.85MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Neonc Technologies Holdings, Inc. filings on SEC EDGAR ↗

6:04 AM ET 8-K
Investor Presentation

Neonc Technologies Holdings Investor Presentation

NeOnc Technologies Holdings, Inc. filed a formal corporate presentation for use in upcoming investor meetings, highlighting its clinical-stage CNS oncology platforms. The filing includes a clinical update for the NEO100 Phase 2a study, reporting an additional patient response that increased the objective response rate from 8.3% to 12.5%.

5:34 PM ET Form 4
Insider Buying

Neonc Technologies Holdings CEO, President Amir F. Heshmatpour Buys $151K of Stock

Amir F. Heshmatpour, CEO, President, bought 30,000 shares of Neonc Technologies Holdings, Inc. at $5.02 a share, worth $151K in total on Nov 13, 2026. Shares held after the trade: 3,353,000 (+0.9%).

Value
$151K
Shares
30,000
Price
$5.02
Role
CEO, President
Holding change
+0.9%
Trade date
Nov 13, 2026
5:01 PM ET 8-K
Business Update

Neonc Technologies Holdings Business Update

NeOnc Technologies announced that CEO Amir Heshmatpour purchased 80,000 shares of common stock in the open market, bringing his total 2026 personal investment to 271,000 shares. Additionally, the company received a Type B End-of-Phase meeting from the FDA scheduled for January 2027 to discuss an accelerated approval pathway for its brain cancer candidate, NEO100.

6:15 AM ET Form 4
Insider Buying

Neonc Technologies Holdings CMO Thomas C. Chen Buys $10K of Stock

Thomas C. Chen, CMO, bought 2,284 shares of Neonc Technologies Holdings, Inc. at $4.38 a share, worth $10K in total on Nov 10, 2026. Shares held after the trade: 29,519 (+8.4%).

Value
$10K
Shares
2,284
Price
$4.38
Role
CMO
Holding change
+8.4%
Trade date
Nov 10, 2026
6:10 AM ET Form 4
Insider Buying

Neonc Technologies Holdings CEO, President Amir F. Heshmatpour Buys $294K of Stock

Amir F. Heshmatpour, CEO, President, bought 70,000 shares of Neonc Technologies Holdings, Inc. at $4.00 to $4.49 a share (average $4.21) in 3 transactions, worth $294K in total between Nov 10, 2026 and Nov 11, 2026. Shares held after the trade: 3,333,000 (+0.3%).

Value
$294K
Shares
70,000
Average price
$4.21
Role
CEO, President
Holding change
+0.3%
Trade date
Nov 10, 2026 to Nov 11, 2026
7:00 PM ET Form 4
Insider Buying

Neonc Technologies Holdings CEO, President Amir F. Heshmatpour Buys $38.6K of Stock

Amir F. Heshmatpour, CEO, President, bought 10,000 shares of Neonc Technologies Holdings, Inc. at $3.86 a share, worth $38.6K in total on Nov 9, 2026. Shares held after the trade: 3,263,000 (+0.3%).

Value
$38.6K
Shares
10,000
Price
$3.86
Role
CEO, President
Holding change
+0.3%
Trade date
Nov 9, 2026
6:04 AM ET Form 4
Insider Buying

Neonc Technologies Holdings CEO, President Amir F. Heshmatpour Buys $231K of Stock

Amir F. Heshmatpour, CEO, President, bought 70,000 shares of Neonc Technologies Holdings, Inc. at $3.17 to $3.39 a share (average $3.29) in 2 transactions, worth $231K in total between Nov 5, 2026 and Nov 6, 2026. Shares held after the trade: 3,253,000 (+1.2%).

Value
$231K
Shares
70,000
Average price
$3.29
Role
CEO, President
Holding change
+1.2%
Trade date
Nov 5, 2026 to Nov 6, 2026
5:02 PM ET 8-K
Financial Results

Neonc Technologies Holdings Financial Results

NeOnc Technologies reported Q3 2026 financial results, highlighting a narrowed net loss of $4.4 million compared to $8.6 million in the prior year period. The company also noted clinical progress with positive topline Phase 2a results for its NEO100 program and a $15 million capital raise completed in September.

Term
Q3 2026

“The third quarter marked a period of meaningful progress for NeOnc, strengthening our clinical programs, our balance sheet and our international presence. In August, we were pleased to report positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint, an important milestone that supports the potential of our intranasal approach to directly address delivery across the blood-brain barrier, one of the greatest challenges in treating brain cancer.”

Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer

“Alongside these clinical achievements, we strengthened the financial and strategic foundation that supports them. In September, we raised $15 million from new and existing healthcare-focused institutional investors and used a portion of the proceeds to redeem all of our Series A Convertible Preferred Stock in cash, eliminating its potential dilution for our shareholders.”

Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer
8:35 AM ET 10-Q
Financial Results

Neonc Technologies Holdings Q3 2026 Results: Net Loss of $4.44M, Loss Narrows

For the nine months ended September 30, 2026, NeoNc Technologies reported a net loss of $27.5 million, an improvement from the $46.6 million loss in the prior year period. The company significantly strengthened its cash position to $6.2 million through various private placements and equity offerings, though it continues to operate with a stockholders' deficit of $13.2 million.

Key figure
Net loss $4.44M
5:01 PM ET 8-K
Business Update

Neonc Technologies Holdings Business Update

NeOnc Technologies announced it will present data from its NEO100 and NEO212 clinical programs at the 31st Annual Meeting of the Society for Neuro-Oncology in November 2026. The presentations will cover Phase 1/2a results for intranasal NEO100 in astrocytoma and Phase 1 safety and PK data for oral NEO212 in recurrent GBM. This filing serves as an announcement of the upcoming presentations and does not disclose the specific clinical results or data points.

5:20 PM ET 8-K
Clinical Trial Data

Neonc Technologies Holdings Clinical Trial Data

NeOnc Technologies reported early clinical improvement in the first pediatric patient treated with its investigational intranasal NEO100 under a Compassionate Care program in Abu Dhabi. The company also announced a Memorandum of Understanding with the Department of Health – Abu Dhabi to cooperate on oncology and CNS therapeutic research.

Counterparty
Department of Health – Abu Dhabi

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.